| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M103792200 |
| P8608 | Fatcat ID | release_sp4ybzecurhfvo2wufzjjg7iei |
| P3181 | OpenCitations bibliographic resource ID | 3975695 |
| P698 | PubMed publication ID | 11477075 |
| P2093 | author name string | R B Kim | |
| R G Tirona | |||
| G Merino | |||
| B F Leake | |||
| P2860 | cites work | Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 | Q22009932 |
| Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide | Q22253972 | ||
| Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family | Q28139520 | ||
| A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters | Q28140566 | ||
| Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6 | Q28141205 | ||
| Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver | Q28611970 | ||
| Pharmacogenomics: translating functional genomics into rational therapeutics | Q33751829 | ||
| Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology | Q33947596 | ||
| The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome | Q34057969 | ||
| Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver | Q34449158 | ||
| Expression cloning of a rat liver Na(+)-independent organic anion transporter | Q34907393 | ||
| 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses | Q34994306 | ||
| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | Q35113118 | ||
| Ethnicity as a variable in epidemiological research | Q36886820 | ||
| Molecular mechanisms of genetic polymorphisms of drug metabolism | Q41455752 | ||
| Identification of functionally variant MDR1 alleles among European Americans and African Americans | Q43705904 | ||
| Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. | Q52295443 | ||
| Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. | Q52534774 | ||
| P433 | issue | 38 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 35669-75 | |
| P577 | publication date | 2001-09-21 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans | |
| P478 | volume | 276 |
| Q90410126 | A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions |
| Q44767175 | A genome-wide search for non-UGT1A1 markers associated with unconjugated bilirubin level reveals significant association with a polymorphic marker near a gene of the nucleoporin family |
| Q28219109 | A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter |
| Q50795222 | A novel matrix for the short-term storage of cells: utility in drug metabolism and drug transporter studies with rat, dog and human hepatocytes. |
| Q33348371 | A piece in the puzzle of personalized medicine |
| Q37908891 | A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? |
| Q33891588 | A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes |
| Q37279044 | Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis |
| Q57106957 | Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems |
| Q37066712 | Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport |
| Q43919929 | An evolutionarily ancient Oatp: insights into conserved functional domains of these proteins |
| Q39145949 | An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure |
| Q36265658 | Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport |
| Q33994570 | Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. |
| Q38798449 | Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. |
| Q28070052 | Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis |
| Q46378129 | Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy |
| Q54373168 | Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. |
| Q35135638 | Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy |
| Q84371927 | Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure |
| Q28027885 | Bile acid transporters: structure, function, regulation and pathophysiological implications |
| Q50644999 | Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. |
| Q44923699 | Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. |
| Q42178200 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions |
| Q91069615 | Clinical Aspects of Transporter-Mediated Drug-Drug Interactions |
| Q31042226 | Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation |
| Q37579733 | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care |
| Q37818151 | Clinical implications of pharmacogenetic variation on the effects of statins. |
| Q38056878 | Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption |
| Q35964012 | Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study |
| Q47099265 | Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study |
| Q40135603 | Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations |
| Q35375045 | Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance |
| Q37960129 | Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions. |
| Q80997948 | Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy |
| Q46655061 | Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers |
| Q57825140 | Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin |
| Q46813708 | Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide |
| Q42757090 | Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. |
| Q41986919 | Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method |
| Q39448926 | Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia |
| Q36419290 | Drug transporters in pharmacokinetics |
| Q83823558 | Drug-induced cholestasis |
| Q54048653 | Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. |
| Q33776950 | Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants |
| Q46436852 | Effect of genetic variants of bilirubin metabolism on the degree of hyperbilirubinemia in African-American newborns |
| Q36645956 | Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. |
| Q54387375 | Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. |
| Q46111551 | Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism |
| Q53855861 | Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. |
| Q48249474 | Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. |
| Q37724381 | Efflux and uptake transporters as determinants of statin response. |
| Q93119620 | Enantiospecific Pharmacogenomics of Fluvastatin |
| Q37876401 | Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs |
| Q34281819 | Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition |
| Q42758868 | Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1) |
| Q57825157 | Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population |
| Q36623470 | Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans |
| Q43940364 | Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method |
| Q26823434 | Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review |
| Q38262203 | Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q35941387 | Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives |
| Q42316513 | Genetic variants associated with gastrointestinal symptoms in Fabry disease. |
| Q37841614 | Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis |
| Q38167710 | Genetics and personalized medicine--a role in statin therapy? |
| Q35889227 | Genetics and the risk of neonatal hyperbilirubinemia: commentary on the article by Huang et al. on page 682. |
| Q36998199 | Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 |
| Q37120923 | Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions |
| Q34415006 | Genome-wide association studies in pharmacogenomics: successes and lessons |
| Q36393911 | Genotype-based clinical trials in cardiovascular disease |
| Q42185876 | Genotyping of OATP2 Variants in a Group of Malaysian Neonates Using High-Resolution Melting Analysis |
| Q37474395 | Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects |
| Q39340828 | Global analysis of genetic variation in SLCO1B1. |
| Q36877910 | HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms |
| Q37680968 | Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects |
| Q35188657 | Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis |
| Q36606137 | Hepatobiliary transporters and drug-induced cholestasis |
| Q38192698 | Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. |
| Q46518742 | Highlights from the latest pharmacogenomic genome-wide association studies |
| Q35052877 | Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study |
| Q73466818 | Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q26741363 | Hyperbilirubinemia in Neonates: Types, Causes, Clinical Examinations, Preventive Measures and Treatments: A Narrative Review Article |
| Q48150626 | Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters |
| Q99604573 | Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers |
| Q34264868 | Identification of amino acids essential for estrone-3-sulfate transport within transmembrane domain 2 of organic anion transporting polypeptide 1B1. |
| Q34603829 | Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity |
| Q45293996 | Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion |
| Q47113473 | Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population |
| Q53611791 | Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? |
| Q34612244 | Impact of OATP transporters on pharmacokinetics |
| Q43571907 | Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects |
| Q38888369 | Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? |
| Q38003174 | Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. |
| Q35575700 | Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution |
| Q39015474 | Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease |
| Q36363124 | Inborn errors of biliary canalicular transport systems |
| Q30571118 | Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data |
| Q57749429 | Influence of Genomic Ancestry on the Distribution of SLCO1B1, SLCO1B3 and ABCB1 Gene Polymorphisms among Brazilians |
| Q53568394 | Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. |
| Q36475040 | Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers |
| Q36687277 | Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans |
| Q52933882 | Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. |
| Q38845004 | Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis. |
| Q36981855 | Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. |
| Q34165400 | Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity |
| Q94503844 | Interindividual Diversity in Expression of Organic Anion Uptake Transporters in Normal and Cirrhotic Human Liver |
| Q39034284 | Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). |
| Q37422685 | Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex |
| Q45082643 | International Transporter Consortium commentary on clinically important transporter polymorphisms. |
| Q38379295 | Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles |
| Q39801648 | Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. |
| Q42207349 | Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms |
| Q54278534 | Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. |
| Q37728163 | Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients |
| Q39657727 | Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1. |
| Q79244001 | Locus‐specific genetic diversity between human populations: An analysis of the literature |
| Q43182515 | Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism |
| Q47395777 | Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function |
| Q36040772 | Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules |
| Q52580571 | Membrane trafficking of the human organic anion-transporting polypeptide C (hOATPC). |
| Q29616802 | Membrane transporters in drug development |
| Q54216256 | No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. |
| Q36536042 | No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone |
| Q40054814 | Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C. |
| Q34360004 | Novel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation. |
| Q93078158 | Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers |
| Q64932041 | Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology. |
| Q47361769 | Organic Ion Transporters and Statin Drug Interactions |
| Q36334805 | Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene |
| Q28212603 | Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties |
| Q47208462 | Organic anion transporting polypeptides of the OATP/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode. |
| Q37137527 | Organic anion uptake by hepatocytes |
| Q38132411 | Organic anion-transporting polypeptides: a novel approach for cancer therapy |
| Q34719036 | PDZK1 binding and serine phosphorylation regulate subcellular trafficking of organic anion transport protein 1a1. |
| Q42726145 | PharmGKB very important pharmacogene: SLCO1B1. |
| Q35645901 | Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing |
| Q102384319 | Pharmacogenetics at Scale: An Analysis of the UK Biobank |
| Q35038052 | Pharmacogenetics in drug regulation: promise, potential and pitfalls |
| Q34983633 | Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances |
| Q38780996 | Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? |
| Q34777362 | Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney |
| Q35297067 | Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response |
| Q40225504 | Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations |
| Q38243175 | Pharmacogenetics of childhood acute lymphoblastic leukemia. |
| Q37880875 | Pharmacogenetics of drug transporters in the enterohepatic circulation |
| Q38933314 | Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q37641869 | Pharmacogenetics of membrane transporters: an update on current approaches |
| Q90267161 | Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q35956177 | Pharmacogenetics-based new therapeutic concepts |
| Q31144283 | Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment |
| Q35164676 | Pharmacogenomic considerations in drug delivery |
| Q26997380 | Pharmacogenomics and cardiovascular disease |
| Q36019193 | Pharmacogenomics and systems biology of membrane transporters |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q35814091 | Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? |
| Q36441493 | Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy |
| Q36416907 | Pharmacogenomics of human OATP transporters |
| Q34983649 | Pharmacogenomics of organic anion-transporting polypeptides (OATP). |
| Q38203774 | Pharmacogenomics, lipid disorders, and treatment options |
| Q54212183 | Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir. |
| Q46472687 | Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism |
| Q35827696 | Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes |
| Q39178447 | Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). |
| Q26829263 | Plasma membrane transporters in modern liver pharmacology |
| Q37113708 | Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China |
| Q37413286 | Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies |
| Q42746762 | Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. |
| Q35080119 | Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers |
| Q39224845 | Precision Cardiovascular Medicine: State of Genetic Testing. |
| Q33437736 | Prediction of hepatic clearance in human from in vitro data for successful drug development |
| Q104130650 | Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia |
| Q43272335 | Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms |
| Q54654987 | Rapid genotyping of the OATP1B1 polymorphisms A388G and T521C with real-time PCR FRET assays. |
| Q46974116 | Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing |
| Q30494155 | Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function by protein kinase C-mediated internalization. |
| Q35634476 | Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition |
| Q37184530 | Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans |
| Q73046888 | Regression to the truth: replication of association in pharmacogenetic studies |
| Q55046512 | Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. |
| Q38001074 | Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review |
| Q28277932 | Risk factors for severe hyperbilirubinemia in neonates |
| Q37074085 | Role of OATP transporters in the disposition of drugs |
| Q36544966 | Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination |
| Q30380794 | Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. |
| Q34579035 | SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers |
| Q36024636 | SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients |
| Q36184009 | SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. |
| Q39622403 | SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients |
| Q88604000 | SLCO1B1 genetic variation and hormone therapy in menopausal women |
| Q55017654 | SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. |
| Q34047278 | SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group |
| Q34340098 | Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates |
| Q44858960 | Sickle cell anemia: time for personalized prescription of hydroxyurea? Focus on "Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics". |
| Q35827517 | Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. |
| Q36349672 | Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition |
| Q34983639 | Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition |
| Q40349386 | So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics |
| Q37951651 | Statin dose in Asians: is pharmacogenetics relevant? |
| Q34608646 | Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing |
| Q27021716 | Systemic therapies for pancreatic cancer--the role of pharmacogenetics |
| Q36212769 | Systems-ADME/Tox: resources and network approaches |
| Q35817004 | The MDR1 (ABCB1) gene polymorphism and its clinical implications |
| Q88910051 | The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics |
| Q41870583 | The Signature Sequence Region of the Human Drug Transporter Organic Anion Transporting Polypeptide 1B1 Is Important for Protein Surface Expression. |
| Q35558999 | The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort |
| Q34216710 | The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. |
| Q34276618 | The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. |
| Q35793721 | The complexities of hepatic drug transport: current knowledge and emerging concepts. |
| Q36020304 | The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin |
| Q37034158 | The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene |
| Q28188146 | The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport |
| Q34468094 | The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics |
| Q34613443 | The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. |
| Q34079760 | The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5. |
| Q46878607 | The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics |
| Q48809049 | The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. |
| Q34631971 | The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins |
| Q38991373 | The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions |
| Q33185578 | The superfamily of organic anion transporting polypeptides |
| Q37627544 | Transporter pharmacogenetics and statin toxicity |
| Q37735146 | Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy |
| Q37862576 | Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions |
| Q36123304 | Transporters and their impact on drug disposition |
| Q47109683 | Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner |
| Q50641149 | Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. |
| Q35164680 | What is next in pharmacogenomics? Translating it to clinical practice |
| Q33714593 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. |
Search more.